

Supplemental Table 3 Baseline demographics, clinical features, and blood laboratory data of patients with coronary artery abnormality (CAA) or without CAA in the acute phase

Demographics, clinical features, and blood laboratory data	CAA(+) in acute phase (n=103)	CAA(-) in acute phase (n=623)	p value*
Age ; months	18 (7-38)	27 (15-44)	< 0.01
< 6months ; n (%)	17 (16.5)	23 (3.7)	< 0.01
< 12months ; n (%)	38 (36.9)	107 (17.1)	< 0.01
Male ; n (%)	57 (55.3)	352 (56.5)	0.970
Days of initial treatment ; day	5 (4-6)	5(4.5-6)	0.80
Incomplete KD ; n (%)	19 (18.4)	56 (9.0)	< 0.01
IVIg resistance ; n (%)	32 (31.1)	119 (19.1)	< 0.01
Resistance of 2nd line treatment ; n (%)	21 (20.4)	22 (3.5)	< 0.01
Plasma exchange ; n (%)	12 (11.7)	7 (1.1)	< 0.01
Pre-max CA diameter ; mm	2.4 (2.0-2.7)	2.0 (1.8-2.3)	< 0.01
Pre-max CA Z score	2.36 (1.34-2.93)	0.84 (0.27-1.42)	< 0.01
Pre-max CA Z score $\geq$ 2.0 ; n (%)	60 (58.3)	6 (1.0)	< 0.01
Pre-max CA Z score $\geq$ 2.5 ; n (%)	49 (47.6)	0 (0.0)	< 0.01
Max CA Z score within 30 days	3.07 (2.69-3.97)	1.19 (0.63-1.75)	<0.01
CAA after 30 days ; n (%)	17 (16.5)	0 (0.0)	< 0.01
White blood cell count (WBC); $\times 10^3$ / μ L	13.9 (10.5-16.4)	13.0 (10.4-16.1)	0.32
Hemoglobin ; g/dL	11.2 (10.3-11.9)	11.5 (10.9-12.2)	< 0.01
Platelet count ; $\times 10^4$ / μ L	34 (27.8-40.5)	32.8 (27.3-39.9)	0.21
Aspartate aminotransferase (AST) ; U/L	34 (27-93)	34 (27-66)	0.62
Alanine aminotransferase (ALT) ; U/L	32 (16-115)	23 (13-94)	0.03
Total bilirubin ; mg/dL	0.6 (0.5-1.0)	0.6 (0.4-0.8)	0.07
Sodium ; mmol/L	134 (132-137)	135 (133-136)	0.40
C-reactive protein (CRP) ; mg/L	9.7 (5.2-13.5)	6.9 (4.0-10.4)	< 0.01
Triglyceride ; mg/dL	94 (77-123)	94 (77-118)	0.49
Total cholesterol ; mg/dL	134 (117-160)	145 (129-162)	< 0.01
HDL cholesterol ; mg/dL	30 (23-37)	33 (26-41)	0.03

* Kruskal-Wallis or Chi-squared test